Pliant Therapeutics, Inc.

The busy week for the idiopathic pulmonary fibrosis (IPF) space has continued apace with the news that Roche is selling off rights to one of the two drugs currently approved for the debilitating and f

Pliant Therapeutics' plans for bexotegrast are up in the air after the company voluntarily paused elements of a Phase IIb/III trial of the idiopathic pulmonary fibrosis (IPF) drug on the less-than-cle

Who: Akari Therapeutics/Peak Bio What: Two struggling, publicly traded biotechs will combine in an all-stock merger of equals. Why: The combined firm, which will boast a Phase III C5/LTB4 inhibit

The annual meeting of the European Respiratory Society (ERS) will take place in Milan, Italy, on 9-13 September. Data for the late-breakers are still under wraps, but several will be of interest. One